Skip to main content
Top
Published in: Endocrine Pathology 1/2014

01-03-2014

Editorial: The Birth of Endocrine Pathology

Authors: Kalman Kovacs, Sylvia L. Asa

Published in: Endocrine Pathology | Issue 1/2014

Login to get access

Excerpt

During the last 50 years, phenomenal progress was achieved in the better understanding of a large number of diseases including those of the endocrine glands. Previously unknown hormones were discovered; new methods were developed to measure hormone levels in blood, body fluids, and tissues; and new information emerged relating to the functions of hormones and their regulation. Research focused on animal experiments moved from observational to interventional as the ability to engineer animal models developed. With progress towards personalized care, the investigation of primary human samples became the basis for targeted therapies and precision medicine; newly introduced imaging methods and substantial advances in surgical techniques assumed fundamental importance. …
Metadata
Title
Editorial: The Birth of Endocrine Pathology
Authors
Kalman Kovacs
Sylvia L. Asa
Publication date
01-03-2014
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2014
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-013-9249-8

Other articles of this Issue 1/2014

Endocrine Pathology 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine